培美曲塞二线治疗老年晚期非小细胞肺癌的疗效分析

Pemetrexed as Second-line Treatment of Elderly Patients with Advanced Non-small Cell Lung Cancer

目的评价培美曲塞二线治疗老年晚期非小细胞肺癌的疗效和不良反应。方法 30例老年晚期非小细胞肺癌患者接受培美曲塞500 mg/m2静脉滴注,第1天;3周为1个周期。至少2个周期后评价疗效及不良反应。结果可评价疗效者30例,治疗后获得完全缓解(CR)0例,部分缓解(PR)4例,稳定(SD)14例,进展(PD)12例,总有效率(RR)为13.3%(4/30)。临床获益率为60.0%(18/30)。中位疾病进展时间(TTP)为3.1个月,中位生存期(MST)为7.5个月。主要不良反应为骨髓抑制。结论培美曲塞二线治疗老年晚期非小细胞肺癌疗效肯定,且不良反应可耐受。

Objective To evaluate the efficacy and toxicities of pemetrexed as second-line treatment of elderly patients with advanced non-small cell lung cancer.Methods Thirty elderly patients with advanced non-small cell lung cancer were treated with pemetrexed 500 mg/m2 on day1.The chemotherpy repeated every 3 weeks.Efficacy and toxicities were reviewed after at least 2 cycles of chemotherapy.Results All the patients could be included for response rate and the overall response rate was 13.3%（4/30） with 0 case of complete response（CR） and 4 of partial response（PR）,14 of steadiness（SD） and 12 of progressive disease（PD）.The clinical benefit rate was 60.0%（18/30）.Median time to progress（TTP） was 3.1 months,median survival time（MST）was 7.5 months.The main adverse reactions were myelosuppression.Conclusion Pemetrexed is well tolerated and effecitive as second-line treatment of elderly patients with advanced non-small cell lung cancer.